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The stress polarity signaling (SPS) pathway serves as a
marker and a target in the leaky gut barrier: implications
in aging and cancer
Pradipta Ghosh1,2,3,4 , Lee Swanson1,2, Ibrahim M Sayed5,11 , Yash Mittal1, Blaze B Lim1,2, Stella-Rita Ibeawuchi5,
Marc Foretz6,7,8 , Benoit Viollet6,7,8 , Debashis Sahoo9,10 , Soumita Das5
The gut barrier separates trillions of microbes from the largest
immune system in the body; when compromised, a “leaky” gut
barrier fuels systemic inflammation, which hastens the pro-
gression of chronic diseases. Strategies to detect and repair the
leaky gut barrier remain urgent and unmet needs. Recently, a
stress-polarity signaling (SPS) pathway has been described in
which the metabolic sensor, AMP-kinase acts via its effector, GIV
(also known as Girdin) to augment epithelial polarity exclusively
under energetic stress and suppresses tumor formation. Using
murine and human colon-derived organoids, and enteroid-derived
monolayers (EDMs) that are exposed to stressors, we reveal that the
SPS-pathway is active in the intestinal epithelium and requires a
catalytically active AMP-kinase. Its pharmacologic augmentation
resists stress-induced collapse of the epithelium when challenged
withmicrobes ormicrobial products. In addition, the SPS-pathway is
suppressed in the aging gut, and its reactivation in enteroid-derived
monolayers reverses aging-associated inflammation and loss of
barrier function. It is also silenced during progression of colorectal
cancers. These findings reveal the importance of the SPS-pathway in
the gut and highlights its therapeutic potential for treating gut
barrier dysfunction in aging, cancer, and dysbiosis.
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2020 | Accepted 22 January 2020 | Published online 10 February 2020
Introduction
The gut is a complex environment; the gut mucosa maintains immune
homeostasis in physiology by serving as a barrier that restricts access of
trillions of microbes, diverse microbial products, food antigens, and
toxins to the largest immunesystem in thebody. The intestinal barrier is
the largestmucosal surface that separates diverse stressors (trillions of
microbes, toxins, and food antigens) on one side from the largest
immune system on the other. A compromised gut barrier allows mi-
crobes and unwanted antigens to cross the epithelium and generate
inflammation (systemic endotoxemia), which may contribute to a va-
riety of diseases, ranging from metabolic syndrome and chronic organ
dysfunctions to neurodegenerative diseases and cancers (Yacyshyn
et al, 1996; Barbara, 2006; Camilleri & Gorman, 2007; Sandek et al, 2007,
2008, 2012; Alamet al, 2014; Bischoff et al, 2014; Nouri et al, 2014; Samsam
et al, 2014; van De Sande et al, 2014; Clairembault et al, 2015; Lee et al,
2015; Buscarinu et al, 2016; Xue et al, 2016; Ghosh, 2017). Evidence also
shows that aging-related genes, that is, the sirtuins (SIRTs1, 3, 6), are
critical for the integrity of the gut barrier and for controlling inflam-
mation in the gut (Akimova et al, 2014; Akbulut et al, 2015; Liu et al, 2017b;
Zhang et al, 2018). Despite the traction and the discovery of plausible
targets to strengthen the barrier, for example,myosin light-chain kinase
(Cunningham & Turner, 2012), our knowledge of the underlying
mechanism(s) that reinforce the barrier when faced with stressors is
incomplete, and practical strategies for pharmacologic modulation of
the gut barrier remains unrealized.
The primary factor preventing the free access of stressors to our
immune cells is a single layer of polarized intestinal epithelial cells
strung together in solidarity by cell–cell junctions. Loss of cell polarity
and junctions not only impairs organdevelopment and function but can
also serve as one of the first triggers for oncogenesis (Martin-Belmonte
& Perez-Moreno, 2012). Establishment, maintenance (at baseline), and
augmentation (upon stress) of epithelial barriers are achieved by sig-
naling pathways that regulate polarization of epithelial cells. Epithelial
polarity is established and maintained by a set of evolutionarily con-
served signaling pathways whose integration in space and time dictates
overall epithelial morphogenesis (St Johnston & Sanson, 2011), for ex-
ample, CDC42 and PAR proteins, such as the PAR3-PAR6-aPKC polarity
complex (Wodarz & Nathke, 2007) and pathways that regulate mem-
brane exocytosis and lipid modifications (Wodarz & Nathke, 2007;
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St Johnston & Ahringer, 2010). Augmentation of epithelial polarity re-
quires an additional signaling component which is triggered exclusively
in response to stress. Three studies (Zhang et al, 2006; Lee et al, 2007;
Zheng & Cantley, 2007) reported a role of AMP-activated protein kinase
(AMPK) in the maintenance of epithelial cell polarity and barrier
functions in the context of stress; who or what was its effector at the
cell–cell junctions remained unknown. A decade later, Aznar et al (2016)
demonstrated that GIV (G-α interacting vesicle–associated protein, also
known as Girdin), amultimodular polarity scaffold protein is a substrate
of AMPK and defined the molecular mechanisms by which the AMPK-
GIV signaling axis protects the epithelium by stabilizing tight junctions
(TJs) and preserving cell polarity when challenged with energetic stress.
Using MDCK cells as a model of polarized mammalian cells, Aznar et al
(2016) showed that energetic stress triggers localized activation of AMPK
at the tricellular TJs which mark the most vulnerable cell–cell contacts
in sheets of polarized cells. A significant part of the junction-stabilizing
effects of AMPK agonists such as 5-Aminoimidazole-4-carboxamide
ribonucleotide (AICAR) and metformin during energetic stress (Zhang
et al, 2006; Zheng& Cantley, 2007) appeared to bemediated by AMPK via
its downstream effector, pS245-GIV (Aznar et al, 2016). Based on these
findings, the AMPK → pS245 GIV signaling axis was named the “Stress
Polarity Signaling (SPS)-Pathway.” It was shown that the SPS-pathway
inhibits oncogenic transformation and anchorage-independent growth
of cancer cells; disruption of this pathway via mutations that make GIV
non-phosphorylatable helps tumor cells escape such inhibition and
gain proliferative advantage. These findings led to the conclusion that
the SPS-pathway integrates stress-sensing and augmention of cell
polarity pathways to serve as a deterrent to oncogenesis.
Despite these insights, the pathophysiologic relevance of such
integration illustrated exclusively in cell lines, remained unclear. Here,
we used a near-physiologic model system (co-cultures of microbes
with mouse and human organoids) to assess the importance of this
pathway in the gut lining. Our studies reveal the physiologic impor-
tance of the SPS-pathway in the maintenance of the gut barrier
function and consequences when it is dysregulated. Findings also
reveal the therapeutic potential of AMPK agonists such asmetformin in
strengthening the gut barrier. Over the years, the beneficial (protective)
effect of multiple nutritional components, dietary supplements, and
pharmacologic agents, including thewidely prescribed AMPK-activator,
metformin, on intestinal permeability in health and disease has been
investigated; all studies converge on AMPK activation as a common
pre-requisite for rendering such protection (reviewed in (Ghosh (2017)).
Taken together with these prior works, our findings provide an impetus
for harnessing the diagnostic and therapeutic potential of the SPS-
pathway in the setting of a variety of diseases that are associated with
increased intestinal permeability such as inflammaging and cancer.
Results and Discussion
The SPS-pathway is active in the colon epithelium and requires
the catalytic activity of AMPK
First, we asked if the SPS-pathway is active in the epithelial lining of
the human colon. To this end, we performed immunohistochemistry
(IHC) using the previously validated (Aznar et al, 2016) anti-pS245-GIV
antibody on formalin-fixed paraffin-embedded (FFPE) colon tissues
obtained during routine colonoscopy for colon cancer screening (Fig
1A). Although all tissues were histologically confirmed as “normal,”
some of them were from patients with type II diabetes on chronic
therapy with metformin at doses ranging from 500 to 1,500 mg/d. We
preferred the use of pS245-GIV as a “surrogate marker” of the SPS-
pathway (as opposed to other global anti-phospho-AMPK anti-
bodies) because pS245-GIV was previously determined (Aznar et al,
2016) to be the TJ-localized substrate of AMPK activity which is both
necessary and sufficient for protecting TJs from stress-induced
collapse. It offers a way to specifically monitor AMPK’s TJ-stabilizing
effect as opposed to its general effect on cellular bioenergetics. In fact,
a side-by-side comparison of the two targets showed that although
pS245GIV remained associated with TJs in a sustainedmanner, pAMPK
is activated only transiently at tricellular contact site and then shows a
cytosolic staining pattern around disrupted TJs (Aznar et al, 2016). We
found that although the intensity of staining varies among patients, a
larger proportion of patients onmetformin displayed positive staining
and at a stronger intensity compared with the cohort of patients, not
on metformin (Figs 1A and S1). These findings indicate that the SPS-
pathway, as determined by pS245-GIV as a surrogate marker, is active
in the human colon epithelium and that although its degree of ac-
tivation varies considerably in the normal colon, it appears to be
consistently enhanced in patients exposed to the widely prescribed
AMPK-agonist metformin.
To translate the physiological implications of the observations
made using polarized MDCK monolayers (Aznar et al, 2016), we used
an ex vivo near-physiologic model system called the “gut-in-a-
dish” (see the legend and Fig 1B). In this model, crypt-derived
stem cells isolated from human or mouse colon (see the Ma-
terials and Methods section) were used to generate organoids
and later differentiated into polarized enteriod-derived mono-
layers (EDMs). These EDMs have been validated as model systems
that closely resemble the physiologic gut lining in which all cell
types (enterocytes, goblet, Paneth enteroendocrine, and tuft cells)
are proportionately represented (Sato et al, 2009; Miyoshi &
Stappenbeck, 2013; Foulke-Abel et al, 2014; Noel et al, 2017; Yu
et al, 2017). We used this “gut-in-a-dish” model to rigorously
interrogate the impact of various stressors on the integrity of
the gut barrier and cellular processes, using readouts illustrated
in Fig 1B. Using pS245-GIV as a marker, we confirmed that the SPS-
pathway is active in the EDMs, colocalized with the TJ protein,
occludin, as previously shown in MDCK cells; (Aznar et al, 2016).
When we treated the EDMs with metformin, the pathway was sig-
nificantly enhanced—whereas immunofluorescence studies (Figs
1C-Left and S2) showed a approximately fivefold to sixfold increase
in the intensity of occludin staining, immunoblots (Fig 1C-Right)
showed a peak increase in pS245 GIV and pAMPK up to approximately
twofold to threefold at 4 h.
Next, we asked if activation of the SPS-pathway in the gut epi-
thelium requires the catalytic activity of AMPK. We assessed the
levels of pS245-GIV in enteroids using two parallel approaches: 1)
We generated enteroids from AMPKα1/2-Villin-Cre mice (generated by
Benoit Viollet, Institut National de la Sante´ et de la Recherche
Me´dicale (French Institute of Health and Medical Research) [INSERM];
manuscript in preparation) which lack both the α-isoforms that en-
code the catalytic subunits of the heterotrimeric kinase. 2) We used a
well-validated direct agonist of AMPK, A-769662 (Cool et al, 2006), for
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which the structural basis for activation of the heterotrimer is
known (Xiao et al, 2013). We found that neither metformin nor A7
could induce pS245-GIV in enteroids devoid of AMPKα1/2 (Fig 1D).
Compared with EDMs fromWTmice, EDMs derived from AMPKα1/2-
Villin-Cre mice showed impaired barrier integrity and higher
paracellular permeability, as reflected by low trans-epithelial
electrical resistance (TEER; Fig 1E), absence of pS245-GIV stain-
ing at the TJs, and aberrant TJ morphology detected using occludin
a bona fide TJ protein (“burst” appearance of tricellular TJs; see
arrowheads, Fig 1F). Although pS245GIV was virtually absent at TJs,
some nuclear speckles were observed in AMPKα1/2-Villin-Cre EDMs,
the significance of which remains unknown. Furthermore, when we
treated the WT or AMPKα1/2-Villin-Cre EDMs with A-769662, the SPS-
pathway was enhanced in the WT EDMs, as determined by increased
intensities of both occludin and pS245GIV, but the pathway could not
be rescued in the AMPKα1/2-Villin-Cre EDMs (Fig S3). The AMPK ag-
onists also activated the SPS-pathway in human EDMs (Fig 1G). To-
gether, these results using a combination of AMPK-depleted EDMs and
highly specific AMPK agonist demonstrate that the SPS-pathway, as
determined by the abundance of pS245-GIV in the gut epithelium,
Figure 1. The stress polarity signaling (SPS) pathway is active in the gut lining, and its pharmacologic augmentation requires the catalytic activity of AMP-kinase.
(A) Left: The SPS-pathway was evaluated in normal adult colon by immunohistochemistry on FFPE colonic biopsies using anti-pS245-GIV, and the staining intensity in the
epithelium was scored (see Fig S1). Bar graph displays the proportion of patients in each group with varying intensities of staining. Two-sided Fisher’s exact test was used to
calculate significance. Right: Representative images are presented from healthy adult without metformin (lowest “0” staining) and with metformin (highest “>3+” staining)
within the cohort. (B) Schematic showing the key steps involved during the development of the stem cell-based organoid model, “gut-in-a-dish.” Fresh biopsies obtained
from the colons of mice and humans (STEP 1) are used as source of stem cells to grow organoids (STEP 2). Organoids are differentiated into polarized enteroid-derived
monolayers (EDMs; STEP 3) for co-culture studies with microbes and microbial products (exposed apical surface) to mimic the gut lumen in physiology and enable the
assessment of barrier integrity (STEP 4). (C) Left: Murine EDMs treated withmetformin for 0, 1, 4, and 16 h were fixed; stainedwith anti-pS245-GIV (red; a surrogate measure of
the SPS-pathway), occludin (green; a bonafide tight junction [TJ] marker), and nucleus (DAPI); and analyzed by confocal microscopy. Images (left) display the findings at 0 and
16 h; see Fig S2 for all intermediate time points and for quantification of pixel intensity of occludin staining at TJs. Boxed areas were analyzed by 3D surface plot (Image J). Scale
bars = 10 μm. Right: Immunoblots (right) on whole cell lysates of murine enteroids treated for 0, 1, 4, and 16 h incubated with anti-phospho(p) and anti-total(t) GIV and anti-
AMPK proteins, and α-tubulin (as loading control) confirm activation of the SPS pathway in murine enteroids. Images and immunoblots presented are representative of ~3–5
independent experiments. (D) Enteroids isolated from WT or AMPKα1/2−/−mice were treated or not (“Un”) with the indicated pharmacologic agonists of AMPK (1 mM Met,
metformin; 100 μMA7, A769662) for 4 h before lysis. Equal aliquots of whole cell lysates were analyzed for activation of AMPK and the SPS-pathway by immunoblotting. (E)Bar
graphs display the change in trans-epithelial electrical resistance (TEER) across EDMs prepared from WT and AMPKα1/2−/−mice. Findings were analyzed by one-way ANOVA
followed by multiple comparison test. Error bars represent mean ± SEM, n = 3; **P < 0.01. (B, F)Murine EDMs derived from WT or AMPKα 1/2−/− mouse colons were prepared as
described in (B),fixed, and analyzed for the integrity of theepithelial tight junctions and theSPS-pathwayusing anti-occludin andanti-pS245GIV, respectively, and imaged by
confocal microscopy. Left: Images displayed are representative of three independent experiments. Arrowheads point to “burst” pattern of occludin staining at the disrupted
tricellular TJs. Scale bars = 10 μm. Right: RGB profile plot (right) indicate the co-localization of pS245-GIV and occludin as assessed using an ImageJ plug-ins. See also Fig S3 for
the effect of AMPK agonist on EDM. (G) Human EDMs were either untreated or treated with A-769662 (100 μM) for 16 h; fixed; stained with anti-pS245-GIV (red; a surrogate
measure of the SPS-pathway), occludin (green; a bonafide TJ marker), and nucleus (DAPI); and analyzed by confocal microscopy. Left: Images displayed are representative of
three independent experiments. Scale bars = 10 μm. Right: RGB profile plot (right) indicated the co-localization of pS245-GIV and occludin as assessed using an ImageJ plug-ins.
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requires the metabolic kinase AMPK, and its absence compromises the
integrity of the epithelial barrier.
The SPS-pathway protects the gut barrier against diverse
stressors such as microbes and microbial products
Next, we used the “gut-in-a-dish” model to study the role of the
SPS-pathway in EDMs under stress. Our choice of stressors included
those that are physiologically encountered within the gut lumen,
for example, a) live commensal microbes (Escherichia coli; Fig
2A–C), b) microbial outer membrane components (LPS; Fig 2D
and E) and H2O2 (Fig 2D and F); the latter induces reactive oxy-
gen species in ways that mimic the host response to dysbiosis or in
response to injury or inflammation. EDMs were either treated or not
with metformin followed by exposure to each stressor. EDMs were
assessed for barrier integrity by analyzing the same sample by two
Figure 2. Pharmacologic augmentation of the stress polarity signaling (SPS) pathway protects the gut barrier against diverse stressors such as microbes and
microbial products.
(A) Mouse enteroid-derived monolayers (EDMs) were infected with E. coli K12 with or without prior exposure to metformin (1 mM for 16 h); fixed; stained with anti-pS245-
GIV (red; a surrogate measure of the SPS-pathway), occludin (green; a bona fide tight junction [TJ] marker), and nucleus (DAPI); and analyzed by confocal microscopy. Left:
Images displayed are representative of three independent experiments. (A) Co-localization of pS245-GIV and occludin was assessed using ImageJ plug-ins: RGB profile
plot (A-middle) and 3D surface plots (A-right). Scale bars = 10 μm. (A, B) Bar graphs display the % of TJs that appeared broken and/or splitting (“burst”-appearing) on the
y-axis encountered in 8–10 randomly chosen fields from three independent experiments in (A). Findings were analyzed by one-way ANOVA followed by multiple
comparisons test. Error bars represent mean ± SEM, n = 3; **P < 0.01. (A, C) Bar graphs display the change in TEER across the EDMs in (A). Findings were analyzed by one-
way ANOVA followed by multiple comparison test. Error bars represent mean ± SEM; n = 3; **P < 0.01. (D) Mouse EDMs pretreated (or not) with metformin (1 mM for 16 h)
were exposed to LPS or H2O2, as indicated; fixed; stained with anti-pS245-GIV (red; a surrogate measure of the SPS-pathway), occludin (green; a bonafide TJ marker), and
nucleus (DAPI); and analyzed by confocal microscopy. Left: Images displayed are representative of three independent experiments. Scale bars = 10 μm. Right: Co-
localization of pS245-GIV and occludin was assessed using ImageJ plug-ins, RGB profile plot. (D, E, F) Bar graphs display the change in TEER of the EDMs after LPS (E) or
H2O2 (F) treatment shown in (D). Findings were analyzed by one-way ANOVA followed by multiple comparisons test. Error bars represent mean ± SEM; n = 3; **P < 0.01.
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assays: a) periodic measurements of TEER and b) immunofluo-
rescence with pS245-GIV and occludin to assess the SPS-pathway
and TJ morphology, respectively. We continued to monitor occludin
as a readout of TJ morphology because this integral membrane
protein allows us to not just visualize but also quantify the degree
of TJ disruption (“burst” tricellular TJs where three or more cells
come in contact [Furuse et al, 2014]); the tricellular TJs appear to be
the regions where earliest evidence of disruption can be visualized/
assessed first. Also, prior work (Aznar et al, 2016) showed that under
stress, active AMPK was detected transiently at the TJs of tricellular
contact, as determined by colocalization of phospho-AMPK with
occludin. We found that all stressors induced barrier disruption in
untreated EDMs, as determined by occludin staining (Fig 2A, B, and
D) and by the observed drops in TEER (Fig 2B, C, E, and F). Pre-
treatment of EDMs with metformin showed SPS-pathway activation
(pS245), maintenance of TJ architecture (occludin), and preserva-
tion of barrier integrity (TEER). We conclude that treatment with
metformin resists barrier collapse in all stress-inducing conditions
tested, implicating the barrier-protective role of the SPS-pathway
in the gut epithelium.
The SPS-pathway is suppressed in the aged gut; its loss triggers
inflammation
Among the various organ systems that decline during aging, dys-
function of the intestinal barrier has been correlated with increasing
age in a variety of species. For example, dysfunction of the intestinal
barrier predicts impending death in individual flies regardless of
their chronological age (Rera et al, 2012). Much like humans, dys-
regulation of barrier in these flies shows an age-related increase in
immunity-related gene expression (e.g., IL-6) (Rera et al, 2012). Evi-
dence also shows that intestinal barrier dysfunction during aging is
conserved in worms (Caenorhabditis elegans), fish (Danio rerio)
(Tricoire &Rera, 2015; Dambroise et al, 2016), andmammals (rats [Katz
et al, 1987] and baboons [Tran and Greenwood-Van Meerveld, 2013]),
thus raising the possibility that it may also be the case in humans. To
investigate this, we first characterized human enteroids derived from
term male fetuses and “normal” colon biopsies from elderly male
subjects (Fig 3A) for transcript expression levels of SIRTs 1 and 6, two
key aging/longevity related families of proteins with either mono-
ADP-ribosyltransferase or deacylase activity, that is, sirtuins because
previous lifespan studies carried out using yeast, worms, and flies as
model organisms have demonstrated that sirtuins are evolutionarily
conservedmediators of longevity (Kaeberlein et al, 1999; Tissenbaum
& Guarente, 2001; Rogina & Helfand, 2004). Both SIRTs have been
shown to regulate inflammation in the gut (Akimova et al, 2014; Lo
Sasso et al, 2014; Wellman et al, 2017; Zhang et al, 2018). We found that
compared with fetal EDMs, aged EDMs expressed less SIRT1 and 6 (Fig
3B-Left, Middle), consistent with the previous observations of their
decline in the aged gut (Liu et al, 2017a; Igarashi et al, 2019). Because
age-associated changes in gutmicrobiome composition is correlated
with increases in the pro-inflammatory marker serum monocyte
chemoattractant protein (MCP-1) (Conley et al, 2016), which in turn
has been implicated in aging-related macrophage dysfunction
(Thevaranjan et al, 2017), we analyzed this cytokine in the aged EDMs.
We found that MCP-1 transcript levels were increased in aged EDMs
relative to fetal EMDs (Fig 3B-Right).
Increased intestinal leakiness in the aged gut has been docu-
mented (Valentini et al, 2014). Therefore, next, we analyzed the
barrier integrity of and the status of the SPS-pathway in the aged
EDM. We found by confocal microscopy that TJs were more fre-
quently disrupted in the aged compared with fetal EDMs (Fig 3C;
occludin signal) and that the SPS-pathway is suppressed (Fig 3C;
pS245-GIV signal was virtually undetectable). Treatment of the aged
EDMs with metformin restored the SPS-pathway, repaired the
“burst” TJs (visualized by occludin staining) (Fig 3C), and increased
TEER (Fig 3D). Pharmacologic activation of the SPS-pathway either
with metformin or the AMPK-specific activator, A-769662 (Fig 3C–H),
reduced the leaky TJ-protein, claudin-2 (CLDN2) (Fig 3E), and sup-
pressed proinflammatory cytokines (IL8, IL6, and MCP1) (Fig 3F–H).
These findings indicate that pharmacologic activation of AMPK and
restoration of the SPS-pathway is sufficient to reduce pro-
inflammatory cytokines that are seen in the aged EDMs. Finally,
we confirmed that the SPS-pathway is indeed suppressed in the
aged gut lining, as determined by IHC on FFPE colon tissues ob-
tained during routine colonoscopy from patients representative of
various age groups (Fig 3I). Taken together, we conclude that the
SPS-pathway is suppressed in the aged gut epithelium, and such
suppression is permissive to a pro-inflammatory program.
The SPS-pathway is suppressed during colorectal cancer (CRC)
initiation and progression
Previously, Aznar et al (2016) indicated the tumor-suppressive
property of the SPS-pathway. Here, we investigated the activa-
tion status of the tumor-suppressive SPS-pathway during CRC
initiation and progression. Because TJ-localized pS245-GIV serves
as a functional molecular marker that reflects the activation state of
the SPS-pathway, we carried out IHC with anti-pS245-GIV on FFPE
colon tissues from various stages of normal-to-cancer progression
in the colon (Fig 3J). Phospho-S245-GIV was undetectable in almost
all advanced adenomas and all CRCs analyzed (Fig 3K and L), in-
dicating that the SPS-pathway is lost or silenced during CRC pro-
gression. This finding is consistent with our previous findings (Aznar
et al, 2016) demonstrating the tumor-suppressive property of the
SPS-pathway in 3D-cultured DLD1 CRC cell lines. It is important to
note that the pattern of pS245GIV staining is strikingly different
from the levels of total GIV during CRC initiation and progression;
we have previously shown that GIV mRNA and protein generally
decreases first during polyp formation and progression and sub-
sequently increases during CRC progression to metastasis (Ghosh
et al, 2010). We and others have shown that increased levels of GIV
in established CRCs correlate with aggressive features (Garcia-
Marcos et al, 2011b; Jun et al, 2013; Aznar et al, 2016; Barbazan
et al, 2016; Ghosh et al, 2016; Lu et al, 2018), for example, shorter
metastasis-free survival, chemoresistance, and stemness, largely
attributed to its ability to scaffold multi-receptor signaling cascades
and enhance them via G protein intermediates to trigger epithelial
mesenchymal transition (reviewed in Ghosh (2015)). Taken together,
the loss of pS245 GIV early during polyp to CRC progression un-
derscores how GIV may serve as a tumor suppressor when localized
to TJs in the polarized normal epitheliumbefore it assumes its role as
an enhancer of epithelial–mesenchymal transition and stemness in
established CRCs.
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Figure 3. Stress polarity signaling pathway is impaired in the aging gut and during the initiation and progression of colorectal cancers.
(A, B, C, D, E, F, G, H) Schematic showing the profile of human enteroid-derived monolayers (EDMs) used in panels (B, C, D, E, F, G, H). Term fetus is indicated as age 0 yr.
(B) Fetal (0 yr; n = 3 subjects) and aged (~50–70-yr old; n = 3 subjects) human EDMs were analyzed for aging molecules, Sirtuins (SIRT)1 and 6, and MCP-1 by qRT-PCR. Data
displayed as mean ± SEM from three independent experiments. Findings were analyzed by one-way ANOVA followed by multiple comparisons test. * = P < 0.05. (B, C) EDMs
in (B) were pretreated or not with metformin (1 mM for 16 h); fixed; stained with anti-pS245-GIV (red; a surrogate measure of the stress polarity signaling-pathway),
occludin (green; a bonafide tight junction marker), and nucleus (DAPI); and analyzed by confocal microscopy. Above: Images displayed are representative of three
independent experiments. Scale bars = 10 μm. Co-localization of pS245-GIV and occludin was assessed using ImageJ plug-ins and below, 3D surface plots. (C, D) Bar graphs
display the change in TEER of the EDMs in (C). Findings were analyzed by two-way ANOVA followed by multiple comparisons test. Error bars represent mean ± SEM; n = 3;
**P < 0.01. (E, F, G, H) The aged (69-yr-old) human EDMs were treated or not (“Untr”) with metformin (1 mM) or A7 (A769662; 100 μM) for 16 h before analyzing them for the
levels of expression of CLDN2 (claudin-2), IL-8, IL-6, and MCP-1 by qRT-PCR. Data displayed as mean ± SEM from three independent experiments normalized to untreated
control. Findings were analyzed by two-way ANOVA followed bymultiple comparisons test. * = P < 0.05; ** = P < 0.01. (I) FFPE human colon tissues representing young (<50
yr; n = 14) or aged (>50 yr; n = 18) were analyzed for pS245-GIV by immunohistochemistry, and the staining intensity in the epithelium was scored (see Fig 1 Supplement 2).
Bar graph displays the proportion of patients in each group with varying intensities of staining. Two-sided Fisher’s exact test was used to calculate significance. (J, K, L) FFPE
human colon tissues representing normal, adenomas, and carcinomas (schematic, J) were analyzed for pS245-GIV by immunohistochemistry. Bar graph (K) displays the
proportion of samples in each category that stained positive. Two-sided Fisher’s exact test was used to calculate significance. (L) Images representative of each category
are displayed (L). Panels on the right are magnified boxed areas of the images on the left. Scale bar = 100 μm.
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Conclusion
The importance of the gut barrier has gained so much traction in
the past decade that it has ushered in the dawn of “barriology”
(Tsukita et al, 2008). The current thinking in the field of “barriology”
is that chronic systemic endotoxemia, due to a compromised gut
barrier in the setting of stress, impacts multiple diseases. Microbial
dysbiosis is known to trigger major cellular programs, for example,
loosening of cell–cell junctions, loss of cell polarity, and chronic
inflammation, all of which coordinately fuel the progression of
these chronic diseases. This work reveals the physiologic impor-
tance and therapeutic potential of the SPS-pathway to resist and
reset gutmicrobe triggered programs by fortifying epithelial TJs (see
Summary and working model; Fig 4). Using the combined synergy of
patient-derived tissues and mouse and human organoid-based
models, we showed that the SPS-pathway serves as a protective
host response that is compromised in the aged gut and early during
the initiation of colon cancers.
This work highlights the SPS-pathway as an “actionable pathway”
in the gut barrier. The abundance of TJ-localized pS245-GIV serves
as a reliablemarker of the SPS-pathway and a surrogatemeasure of
the integrity of the gut barrier. These are important findings be-
cause despite decades of research showing the importance of the
gut barrier in health and disease and discovery of plausible targets
(Cunningham& Turner, 2012), our ability to detect and fix a leaky gut
barrier is not currently a practical option in clinical practice. By
demonstrating direct and specific AMPK-agonists as effective
augmentors of gut barrier integrity and by validating pS245-GIV as a
reliable molecular marker to track such pharmacologic augmen-
tation, this work translates the therapeutic and diagnostic potential
of the fundamental discoveries made by Aznar et al (2016).
With regard to the impact of our findings in human diseases,
because chronic low-grade inflammatory status in the aging gut has
led to coining of the term “inflammaging” (Giunta, 2006; Franceschi,
2007; Franceschi et al, 2007; Goto, 2008; Minciullo et al, 2016; Manabe,
2017), our findings suggest that activation of the SPS-pathway may
serve as a strategy to combat this entity. Because the SPS-pathway
was initially characterized as a tumor-suppressive pathway, and we
have now shown that this pathway is silenced early during CRC
initiation, these findings suggest that activation of the SPS-pathway
may serve as a strategy to prevent polyp-to-cancer progression in
the colon. Our findings also raise the possibility that the SPS-
pathway may affect a variety of non-oncologic diseases that are
associated with increased intestinal permeability (reviewed in
Bischoff et al (2014)) such as chronic gastrointestinal inflammation,
Alzheimer’s, Parkinson’s, multiple sclerosis, autism, chronic heart
failure, and obesity and metabolic diseases. All these diseases are
characterized by systemic inflammation due to chronic endotox-
emia that might be triggered by the translocation of endotoxins
from the gut lumen into the host circulation.
By demonstrating the therapeutic potential of metformin as an
activator of the SPS-pathway, our findings revisit the mechanism of
action of this first-line treatment for type II diabetes. Although
metformin (Glucophage) is now the most widely prescribed type II
diabetes drug in the world for its ability to reduce blood glucose
by activating the LKB1-AMPK pathway (Shaw et al, 2005) and
inhibiting hepatic gluconeogenesis (reviewed in Shackelford and
Shaw (2009)), it is also known to exert other effects in an AMPK-
dependent manner: (i) it stabilizes cell–cell junctions and protects
barrier functions of both epithelial and endothelial monolayers in
the setting of a variety of pathologic stressors and (ii) it suppresses
the growth of a variety of tumor cells and embryonic stem cells in
culture and tumor xenografts in mice (reviewed in Shackelford and
Shaw (2009)). Numerous studies using the AMPK-activator, metfor-
min, squarely implicate the AMPK-dependent stress polarity pathway
as amajor therapeutic target in thesemetabolic disorders (Everard et
al, 2013; Buse et al, 2016; Zhou et al, 2016). metformin administration
enhances gut barrier integrity, attenuates endotoxemia, and en-
hances insulin signaling in high-fat fed mice, which accounts for the
beneficial effects of metformin on glucose metabolism, enhanced
metabolic insulin response, and reduced oxidative stress in liver and
muscle of the mice (Zhou et al, 2016). It is possible that the observed
anti-ageing properties of metformin (via multiple widely pleiotropic
effects reviewed in Barzilai et al (2016)), as in the case of obesity and
diabetes, may begin by preserving the gut barrier function, thereby
reducing age-related inflammation and metabolic derangements. If
so, metformin is expected to act via the AMPK-GIV SPS-pathway to
resist aging-related increase in gut permeability. Ongoing clinical
Figure 4. Summary of findings and working model.
Summary and proposed working model for the role
of the stress polarity signaling (SPS) pathway in the gut
barrier. Genetic, epigenetic, or dysbiosis-induced
inhibition of the SPS-pathway leading to stress-
induced tight junction-collapse and loss of cell
polarity. Loss of the SPS-pathway (in aging and during
cancer initiation) is accompanied by collapse of
epithelial tight junctions and loss of cell polarity, which
is permissive to a gene expression signature that
promotes leakiness of the gut barrier (high claudin-
2) and inflammation (MCP1, IL8). Pharmacologic
augmentation of the SPS-pathway with AMPK agonists
may resist and reverse the above.
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trials approved by the Food and Drug Administration (such as Tar-
geting Ageing with Metformin; TAME) are likely to provide the best
opportunity to investigate these possibilities. In fact, one clinical trial
already hints at that. Using a delayed release formulation of met-
formin (metformin DR, which is designed to target the lower bowel
and limit absorption into the blood), it has been shown that met-
formin works largely in the colon; despite the reduced levels of ab-
sorption of metformin DR, this formulation was effective in lowering
blood glucose (Buse et al, 2016). Our findings in human organoid
models not only bridge the gap between murine studies and the
clinical trials on diabetics but also pinpoint a mechanism via which
metformin’s ability to activate AMPK may serve as a therapeutic
strategy to reinforce the gut barrier.
In closing, our findings underscore the importance of the SPS-
pathway in the gut epithelium for the maintenance of cell polarity
and the epithelial barrier. By showing previously how the
SPS-pathway serves as a tumor suppressive pathway (Aznar et al,
2016) and showing here how the SPS-pathway suppresses proin-
flammatory cytokines in the aging gut (“inflammaging”), we have linked
this specialized polarity pathway polarity to epithelium-driven path-
ophysiologic processes. By demonstrating here that the SPS-pathway
is suppressed during aging and during CRC initiation, we implicate a
loss of this pathway as a bona fide pathophysiologic component of
aging and an early event during oncogenesis. Insights gained also
reveal the diagnostic and therapeutic potential of the SPS-path-
way—its pharmacologic augmentation could be exploited as a strategy
for resisting aging, CRC chemoprevention, and presumably for com-
bating a myriad of other diseases that are characterized by chronic
inflammation and endotoxemia arising from a leaky gut barrier.
Materials and Methods
Reagents and antibodies
Unless otherwise indicated, all reagents were of analytical grade and
obtained from Sigma-Aldrich. Custom-designed oligos were obtained
from Valuegene. Antibodies against GIV that were used in this work
include rabbit serum anti-GIV coiled-coil immunoglobulin G (GIV-ccAb
for immunoblotting only) (Le-Niculescu et al, 2005) and affinity-
purified GIV ccAb (Cat. no. ABT80; from EMD Millipore for immuno-
blotting). Mouse mAbs against anti-phospho-(p; Cell Signaling
Technology) and total (t; Abcam) AMPK, and tubulin (Sigma-Aldrich)
were purchased from commercial sources. Rabbit polyclonal an-
tibodies against phospho-S245 GIV were generated commercially
by 21st Century Biochemicals and extensively validated previously
(Aznar et al, 2016). DAPI and antimouse Alexa Fluor 594–coupled
goat secondary antibody for immunofluorescence were purchased
from Invitrogen. Goat antirabbit and goat antimouse Alexa Fluor
680 or IRDye 800 F(ab9)2 for immunoblotting were from LI-COR
Biosciences.
Animal studies
C57BL/6 mice of 6–8 wk age from both genders were used to isolate
intestinal crypts. Animalswerebred, housed, used for all theexperiments,
and euthanized according to the University of California San Diego In-
stitutional Animal Care and Use Committee policies under the animal
protocol number S18086. All methods were carried out in accordance
with relevant guidelines and regulations and the experimental protocols
were approved by institutional policies and reviewed by the licensing
committee.
Human subjects
For immunohistochemical analysis of human tissue specimens,
archived FFPE human colonic biopsies from healthy controls or
patients with adenomas and/or carcinomas were obtained from
the Gastroenterology Division, VA San Diego Healthcare System,
following the protocol approved by the Human Research Protection
Program Institutional Review Board (Project ID# 1132632).
For the purpose of generating adult healthy enteroids, a fresh
biopsy was prospectively collected using small forceps from
healthy subjects undergoing routine colonoscopy for colon cancer
screening. For all the deidentified human subjects, information
including age, ethnicity, gender, previous history of disease, and
medication was collected from the chart following the rules of
HIPAA. Each human participant was recruited to the study following
an approved human research protocol and signed a consent form
approved by the Human Research Protection Program at the
University of California, San Diego, to agree that the colonic
specimens from their colonoscopy will be used to generate an
enteroid line for functional studies.
Isolation, expansion, and culture of organoids from mouse and
human colons
Intestinal crypts were isolated from the colonic tissue specimen
by digesting with collagenase type I (2 mg/ml; Life Technologies
Corporation) and cultured in stem cell–enriched conditionedmedia
(CM) with WNT 3a, R-spondin, and noggin (Sato et al, 2009; Miyoshi &
Stappenbeck, 2013; Mahe et al, 2015). Briefly, the crypts after di-
gestion with collagenase were filtered with a cell strainer and
washed with the medium (DMEM/F12 with Hepes, 10% FBS). After
adding collagenase I solution containing gentamicin (50 μg/ml; Life
Technologies Corporation) and mixing thoroughly, the plate was
incubated at 37°C inside a CO2 incubator for 10 min, with vigorous
pipetting between incubations and monitoring constantly by light
microscopy to confirm by direct observation the dislodgement of
the intestinal crypts from the tissues. The collagenase was inac-
tivatedwithmedia and filtered using a 70-μmcell strainer over a 50-
ml centrifuge tube. Filtered tissue was spun down at 200g for 5 min,
and the media was aspirated. The epithelial units were suspended
in Matrigel (basement membrane matrix; Cat. no. 356235; Corning
Inc.). Cell-Matrigel suspension (15 μl) was placed at the center of the
24-well plate on ice and placed on the incubator upside-down for
polymerization. After 10 min, 500 μl of 50% CM was added. CM was
prepared from L-WRN cells (CRL-3276; ATCC, from the laboratory of
Thaddeus S. Stappenbeck [Miyoshi & Stappenbeck, 2013]) with
Wnt3a, R-spondin, and noggin. Y27632 (ROCK inhibitor, 10 μM) and
SB431542 (an inhibitor for TGF-β type I receptor, 10 μM) were added
to the medium. For the human enteroids, media and supple-
ments were obtained commercially (Cell Applications Inc.), and a
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proprietary cocktail was added to the above medium. The medium
was changed every 2–3 d and the enteroids were expanded and
frozen in liquid nitrogen.
AMPK KO enteroids were isolated from KO AMPKmice specifically
deleted in the intestinal epithelial cells; these mice were generated
at INSERM by crossing Villin-Cre mice with AMPKα1f1/fl/α2fl/fl mice
(manuscript in preparation). As for human studies, ~4–6 healthy
human individuals were used across the experiments testing their
junctional integrity and response to AMPK agonists.
Preparation of EDMs
EDMs were prepared from colon spheroids as previously described
(den Hartog et al, 2016; Suarez et al, 2018 Preprint). Briefly, the
spheroids were trypsinized and the isolated cells were filtered,
counted, resuspended in 5% CM, and plated with Matrigel (1:40
dilution) in the apical part of 0.4-μm polyester membrane transwell
(Cat. no. 3470; Corning) at the density of 2 × 105 cell/well. In some
cases, the EDMs were also differentiated for 2 d in advanced DMEM/
F12 media without Wnt3a but with R-spondin, noggin, B27 and N2
supplements, and 10 μM ROCK inhibitor (Sato et al, 2009). As ex-
pected, this results in a marked reduction in the expression of the
stemness marker Lgr5 in EDMs (Sato et al, 2009).
Bacterial culture
E. coli K12 strain DH10B, pTransSacB (PTA5105), was obtained from
ATCC; the bacteria was cultured on LB agar and LB broth and used to
infect EDM at moi 100.
Infection of EDMs with live microbes
Mouse and human EDMs were prepared as described in the previous
section. EDMs were differentiated for 2 d before treatment with
various chemical activators of AMPK, that is, metformin (1 mM) and,
A-769662 (100 μM) for 16 h. Cultures were then challenged with either
microbial products, that is, LPS (500 ng/ml) and H2O2 (100 μM) or live
microbes (E. coli K12). On the day of infection, the medium in the
basolateral part was also replaced with fresh 5% medium. Trans-
epithelial electrical resistance (TEER) was measured using an
epithelial voltohmmeter Millicell-ERS resistance meter (Millipore)
before and at specific time points after the treatment (0, 4, 8, and
24 h). The supernatant was collected from the basolateral and
apical part of the transwell for cytokine analysis, and the cells were
collected for RNA extraction followed by expression of target genes
by qRT-PCR.
Immunofluorescence
Mouse and human EDM were fixed with cold methanol at −20°C for
20 min, washed once with phosphate-buffered saline and blocked
with IF buffer (0.1% Triton TX-100 and 2mg/ml BSA, in PBS) for 1 h. The
samples were then incubated with primary and then secondary
antibodies as described previously (Ghosh et al, 2008). Dilutions of
antibodies and reagents were as follows: anti-phospho-Ser245-GIV
(pS245-GIV; 1/250), anti-occludin (1/250), anti-claudin-2-1 (1/250),
DAPI (1:1,000), and goat antimouse Alexa Flour (488 and 594)–
conjugated antibodies (1:500). Images were acquired using a Leica
CTR4000 Confocal Microscope with a 63× objective. Z-stack images
were obtained by imaging ~4-μm-thick sections of cells in all channels.
Cross-section images were obtained by automatic layering of indi-
vidual slices from each Z-stack. Red-green-blue (RGB) graphic profiles
were created by analyzing the distribution and intensity of pixels of
these colors along a chosen line using Image J software. All individual
images were processed using Image J software and assembled for
presentation using Photoshop and Illustrator software (Adobe).
Quantification of burst tight junctions was performed by manually
counting the number of total and burst tri-cellular junctions in 8–10
randomly chosen fields in each of three independent experiments.
Results are expressed as the frequency of burst TJs, and a one-way
ANOVA analysis was used to determine significance.
Immunoblotting
For immunoblotting, protein samples were separated by SDS–PAGE
and transferred to Polyvinylidene fluoride (PVDF) membranes
(Millipore). The membranes were blocked with PBS supplemented
with 5% nonfat milk (or with 5% BSA when probing for phos-
phorylated proteins) before incubation with primary antibodies.
Infrared imaging with two-color detection and band densitometry
quantifications were performed using a Li-Cor Odyssey imaging
system exactly as performed previously (Garcia-Marcos et al, 2010,
2011a, 2011c, 2012; Ghosh et al, 2010). All Odyssey images were
processed using ImageJ software (NIH) and assembled into figure
panels using Photoshop and Illustrator software (Adobe).
Immunohistochemistry (IHC)
FFPE tissue sections of 4 μm thickness were cut and placed on glass
slides coated with poly-L-lysine, followed by deparaffinization and
hydration. Heat-induced epitope retrieval was performed using citrate
buffer (pH 6) in a pressure cooker. Tissue sections were incubated with
0.3% hydrogen peroxidase for 15 min to block endogenous peroxidase
activity, followed by incubation with primary antibodies for 30 min in a
humidified chamber at room temperature. Antibodies used for im-
munostaining were anti-pS245 GIV (1:50, antirabbit antibody) and anti-
AMPKα2 (1:50, antirabbit; Abcam). Immunostaining was visualized with
a labeled streptavidin–biotin using 3,39-diaminobenzidine as a chro-
mogen and counterstained with hematoxylin. The samples were
quantitatively analyzed and scored based on the intensity of staining
using the following scale; 0–3, where 0 = no staining, 1 = light brown, 2 =
brown, and 3 = dark brown. Data are expressed as frequency of staining
score, and a chi-squared test was used to determine significance.
Data reproducibility, rigor
Each finding showcased here represents at least 3–5 independent
repeats of experiments conducted on separate days. For ELISA and
qPCR, results represent 2–3 technical repeats on each experiment,
for a total of n = ~3–5 independent experiments. Where immuno-
fluorescence images are shown, representative images from ran-
domly chosen fields are presented.
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Statistical analyses
Data are expressed as the Mean ± SEM. Statistical significance was
assessed with the t test. Statistical significance between datasets with
three or more experimental groups was determined using one-way
ANOVA including a Tukey’s test for multiple comparisons. For all tests,
a P-value of 0.05 was used as the cutoff to determine significance (*P <
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). All experiments were
repeated a least three times, and P-values are indicated in each figure.
All statistical analyses were performed using GraphPad prism 6.1.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900481.
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